Literature DB >> 10794477

A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women.

E Giovannucci1, M N Pollak, E A Platz, W C Willett, M J Stampfer, N Majeed, G A Colditz, F E Speizer, S E Hankinson.   

Abstract

Insulin-like growth factor-1 (IGF-1) is an important mitogen, and IGF binding protein-3 (IGFBP-3) has opposing effects. Acromegalics, who have abnormally elevated levels of IGF-1, are at increased risk of colorectal tumors. Recent studies have found that IGF-1 levels correlate with risk of prostate cancer and colorectal cancer in men, premenopausal breast cancer in women, and lung cancer in men and women. We examined whether prediagnostic plasma levels of IGF-1 and IGFBP-3 influence risk of colorectal cancer and adenoma in women. From 1989 to 1990, a total of 32,826 women from the Nurses' Health Study provided blood specimens that were archived in liquid nitrogen. During 6 years of follow-up from 1989 to 1994, we documented 79 new cases of colorectal cancer, 90 cases of intermediate/late-stage adenoma (> or =1 cm or tubulovillous/villous histology), and 107 cases of early-stage adenoma (<1 cm and tubular histology). After matching controls (2:1 for cancers and 1:1 for adenomas) to cases by age, month of blood draw, fasting status, and indication for endoscopy (for adenoma controls), plasma IGF-1 and IGFBP-3 levels were measured. Controlling for IGFBP-3 level, relative to women in the low tertile of IGF-1, those in the high tertile were at elevated risk of intermediate/late-stage colorectal neoplasia adenoma [multivariate relative risk (RR), 2.78; 95% confidence interval (CI), 0.76-9.76] and cancer (RR, 2.18; 95% CI, 0.94-5.08). Controlling for IGF-1 level, relative to women in the low tertile of IGFBP-3, women in the high tertile of IGFBP-3 were at lower risk of intermediate/late-stage colorectal adenoma (RR, 0.28; 95% CI, 0.09-0.85) and cancer (RR, 0.28; 95% CI, 0.10-0.83). Neither IGF-1 nor IGFBP-3 had any appreciable relation with early-stage adenoma. These analyses indicate that high levels of circulating IGF-1 and particularly low levels of IGFBP-3 are associated independently with an elevated risk of large or tubulovillous/villous colorectal adenoma and cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794477

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  95 in total

1.  Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma.

Authors:  Ying Gao; Hormuzd Katki; Barry Graubard; Michael Pollak; Michael Martin; Yuzhen Tao; Robert E Schoen; Timothy Church; Richard B Hayes; Mark H Greene; Sonja I Berndt
Journal:  Int J Cancer       Date:  2011-11-02       Impact factor: 7.396

2.  Is diabetes a risk factor for colorectal cancer?

Authors:  Hamed Khalili; Andrew T Chan
Journal:  Dig Dis Sci       Date:  2012-04-25       Impact factor: 3.199

Review 3.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.

Authors:  Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson
Journal:  J Clin Endocrinol Metab       Date:  2015-04-03       Impact factor: 5.958

Review 4.  Role of insulin-like growth factor-1R system in colorectal carcinogenesis.

Authors:  Erin A Donovan; Shivaani Kummar
Journal:  Crit Rev Oncol Hematol       Date:  2007-10-31       Impact factor: 6.312

5.  Mesenchymal stem cell-mediated ectopic hematopoiesis alleviates aging-related phenotype in immunocompromised mice.

Authors:  Takayoshi Yamaza; Yasuo Miura; Kentaro Akiyama; Yanming Bi; Wataru Sonoyama; Stan Gronthos; Wanjun Chen; Anh Le; Songtao Shi
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

6.  The effects of genetic variants related to insulin metabolism pathways and the interactions with lifestyles on colorectal cancer risk.

Authors:  Su Yon Jung; Zuo-Feng Zhang
Journal:  Menopause       Date:  2019-07       Impact factor: 2.953

7.  Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741.

Authors:  Charles S Fuchs; Richard M Goldberg; Daniel J Sargent; Jeffrey A Meyerhardt; Brian M Wolpin; Erin M Green; Henry C Pitot; Michael Pollak
Journal:  Clin Cancer Res       Date:  2008-12-10       Impact factor: 12.531

8.  Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis.

Authors:  Theodoros Rokkas; Dimitrios Pistiolas; Panos Sechopoulos; Georgios Margantinis; Georgios Koukoulis
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

9.  Insulin-like growth factor-I and cancer mortality in older men.

Authors:  Jacqueline M Major; Gail A Laughlin; Donna Kritz-Silverstein; Deborah L Wingard; Elizabeth Barrett-Connor
Journal:  J Clin Endocrinol Metab       Date:  2010-01-15       Impact factor: 5.958

10.  Expression levels of insulin-like growth factors 1 and 2 in head and neck squamous cell carcinoma.

Authors:  Xu Zhi; Katarzyna Lamperska; Paweł Golusinski; Nicholas J Schork; Lukasz Luczewski; Wojciech Golusinski; Michal M Masternak
Journal:  Growth Horm IGF Res       Date:  2014-04-22       Impact factor: 2.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.